21.05.2026

Only 20–40% of cancer patients show a durable response to immunotherapy. A major reason is immune exhaustion: when immune defenses are mobilized too long, they lose effectiveness. Researchers at the University of Fribourg have discovered that chemokines - small chemical signals - play a crucial role in signaling when to stop. Their findings are published in Science.